Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Shirmard FO, Pourfaraji SM, Omouri-Kharashtomi M, Amani A

BMC gastroenterology22 Nov 2025Cited by 2 (Europe PMC)

PMID41275083PMCIDPMC12752087DOI10.1186/s12876-025-04496-5PepBankPUB-41275083

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In people with inflammatory bowel disease, semaglutide subgroup analysis showed a significant weight reduction from baseline.
In plain wordsIn people with inflammatory bowel disease, those treated with semaglutide lost weight on average.
Peptide
Semaglutide
Outcome
DecreaseWeight change in the semaglutide subgroup
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Pooled weight change
−5.59 Kg
semaglutide subgroup
Source sentences
Summary
The weight loss was also significant in the semaglutide subgroup (MRAW: -5.59 Kg; 95% CI, -10.37 to -0.81; P = 0.03; I² = 80.0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Overall, eight retrospective cohort studies involving 1236 patients were included.
Report a problemFND-4127508302

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with inflammatory bowel disease, pooled GLP-1 receptor agonists (semaglutide among them) reduced body weight from baseline.
In plain wordsIn people with inflammatory bowel disease, GLP-1 drugs as a group were linked to weight loss. This pooled result is not for semaglutide alone.
Peptide
Semaglutide
Outcome
DecreasePooled weight change after GLP-1 RA treatment in IBD
Study
n = 1,236
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Pooled weight change
−5.71 Kg
GLP-1 RAs
Source sentences
Summary
The pooled weight change following GLP-1 RAs treatment was - 5.71 Kg (95% CI, -9.56 to -1.86; P = 0.01; I² = 78.0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Overall, eight retrospective cohort studies involving 1236 patients were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4127508301
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with inflammatory bowel disease, pooled GLP-1 receptor agonists (semaglutide among them) reduced BMI from baseline in three studies.
In plain wordsIn people with inflammatory bowel disease, GLP-1 drugs as a group were linked to lower BMI. This pooled result is not for semaglutide alone.
Peptide
Semaglutide
Outcome
DecreasePooled BMI change after GLP-1 RA treatment in IBD
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Pooled BMI change
−2.18 Kg/m<sup>2</sup>
GLP-1 RAs
Source sentences
Summary
the pooled MRAW of three studies on BMI changes showed a significant reduction (-2.18 Kg/m²; 95% CI, -3.66 to -0.69; P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
Overall, eight retrospective cohort studies involving 1236 patients were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4127508303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.